Q2 Earnings Forecast for TNGX Issued By B. Riley

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Research analysts at B. Riley issued their Q2 2025 earnings estimates for shares of Tango Therapeutics in a research note issued to investors on Monday, June 9th. B. Riley analyst Y. Zhi forecasts that the company will earn ($0.35) per share for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.33) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.20.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $4.47 on Wednesday. The stock has a market cap of $484.52 million, a PE ratio of -3.79 and a beta of 1.24. The firm has a fifty day moving average price of $1.81 and a 200 day moving average price of $2.38. Tango Therapeutics has a 1 year low of $1.03 and a 1 year high of $12.02.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.

Hedge Funds Weigh In On Tango Therapeutics

Several large investors have recently made changes to their positions in TNGX. TCG Crossover Management LLC purchased a new position in Tango Therapeutics in the fourth quarter valued at $33,174,000. Boxer Capital Management LLC acquired a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $32,077,000. Gilead Sciences Inc. acquired a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $15,000,000. Farallon Capital Management LLC purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $12,360,000. Finally, Balyasny Asset Management L.P. raised its holdings in Tango Therapeutics by 22.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company’s stock worth $10,133,000 after purchasing an additional 592,000 shares during the period. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.